Despite concerns about the efficacy and safety of checkpoint inhibitors, many biotech companies are advancing them in clinical trials to treat cancer. By 2032, the market for these drugs could reach nearly $189.4 billion. While these inhibitors have shown dramatic results in some cancer patients, they only seem to work for a small percentage. As a result, research is shifting towards combining them with other cancer treatments, and exploring potential new inhibitors. These advances are expected to revolutionize cancer care.
Why ‘subclade K’ could make for a nasty flu season
A new strain of the flu called subclade K could make for a particularly nasty flu season across the country, according to public health experts.
